Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Just For You Why 2 Small Biotechs May Hold the Key to New Cancer TreatmentsBy Nathan Reiff. Published: 3/12/2026. 
Key Points - Iovance and ImmunityBio each have a leading oncology product that has helped to massively boost sales and share prices in recent quarters.
- Despite major gains in recent trading, IOVA and IBRX shares still have at least 70% in upside potential going forward, according to analysts.
- Profitability remains a concern for both companies, even as sales of their top cancer drugs have surged.
- Special Report: Have $500? Invest in Elon's AI Masterplan
Cancer remains one of the greatest medical challenges for biotechnology firms, even as the oncology medicine market is expected to surge to $366 billion in the next eight years. Companies often take a niche approach, developing medicines that target specific cancer types with dedicated mechanisms. Fortunately, a number of promising treatments have shown significant potential—and with that comes the possibility of substantial sales. Two smaller biotech companies have recently seen strong share-price momentum thanks to their leading oncology medicines. Besides offering powerful treatment potential, these drugs may help the firms move toward greater stability beyond penny-stock or otherwise volatile status and potentially toward long-term profitability. In both cases, however, risks remain, making these typical biotech investments high-risk plays that also have the potential for outsized rewards for investors willing to take a chance. Iovance's Powerful Cancer Drug Is Growing, But Production Challenges Are a Hurdle Imagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight. Click here for the full story. Iovance Biotherapeutics Inc. (NASDAQ: IOVA) defied market trends in early March, surging nearly 37% in a week when the S&P 500 teetered and fell about 1%. That rally added to IOVA's year-to-date (YTD) performance, during which shares have more than doubled. Still, the consensus price target of $8.88 implies roughly 71% more upside, suggesting Wall Street expects further gains. The main catalyst for Iovance's move is Amtagvi, a T-cell immunotherapy for certain types of melanoma. Amtagvi was approved in the United States in 2024 and has been building momentum in sales and regulatory progress, with additional approvals likely in the E.U., U.K., and elsewhere. When administered with Proleukin (an IL-2 immunotherapy), management believes Amtagvi has peak U.S. sales potential of over $1 billion. Its potential may extend beyond melanoma: Amtagvi received FDA Fast Track Designation for non-small cell lung cancer and is being explored for other cancers as well. Iovance's recent outperformance was also helped by its Q4 2025 earnings report, issued in late February, in which the company posted narrower-than-expected losses per share and reported $5 million in revenue. For the full year, revenue rose about 30% year-over-year (YOY). That said, Iovance remains a relatively small biotech (about $2 billion market value) and is effectively a penny-stock–level name, so analysts remain cautious: roughly half of its ratings are Hold or Sell. Beyond the usual risks for smaller biotechs, Iovance faces a manufacturing challenge. Amtagvi is a personalized therapy that is costly and complex to manufacture, which could limit margins and delay the company's path to profitability even as demand grows. Massive Sales Growth for ImmunityBio's Bladder Cancer Drug ImmunityBio Inc. (NASDAQ: IBRX) has pulled back about 20% in March; however, in contrast to Iovance, its year-to-date performance dwarfs that rival's. IBRX shares are up nearly 300% in 2026 alone, and analysts remain optimistic. The consensus price target of $13.60 implies roughly 70% upside from current levels even after the recent run-up. ImmunityBio's primary growth driver is Anktiva, a treatment for certain types of bladder cancer. In February, shares jumped after the E.U. regulator granted the drug conditional marketing authorization—the latest in a string of approvals worldwide. Anktiva is already contributing meaningfully to revenue: the drug generated $113 million in sales last year, roughly a 700% year-over-year increase. Like Amtagvi, Anktiva is being studied for potential use in other cancer types, and ImmunityBio is actively exploring additional indications. Despite its recent surge, IBRX remains a speculative, high-risk investment. The company reported a full-year net loss of $351 million for 2025 as R&D expenses continue to mount. Still, analysts are generally more bullish on ImmunityBio than on Iovance: six of seven covering analysts rate the stock a Buy or equivalent. | 
